Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.44 Consensus PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $66.44.

Several research firms have issued reports on JANX. UBS Group assumed coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research report on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Monday, September 16th. Finally, Scotiabank lowered their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now directly owns 282,054 shares in the company, valued at approximately $15,101,171.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock valued at $19,288,666 in the last ninety days. Company insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC acquired a new position in Janux Therapeutics during the first quarter worth about $1,969,000. Janus Henderson Group PLC boosted its position in shares of Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Janux Therapeutics during the 1st quarter worth about $739,000. Virtu Financial LLC purchased a new stake in Janux Therapeutics during the first quarter valued at about $609,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the period. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $54.39 on Friday. Janux Therapeutics has a one year low of $5.65 and a one year high of $65.60. The stock’s 50 day moving average price is $48.09 and its 200 day moving average price is $46.14. The firm has a market capitalization of $2.84 billion, a PE ratio of -59.77 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. The company’s quarterly revenue was up 709.1% compared to the same quarter last year. On average, analysts forecast that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.